Estudo do NATS contribui para inclusão de novos imunoterápicos no SUS

Thumbnail Image

Files

Informe-INCA-2020-399-4-Estudo-do-NATS.pdf (230.79 KB)

Date

2020-09

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

INCA

Abstract

Description

Keywords

Nivolumabe, Nivolumab

Citation

URI

http://sr-vmlxaph03:8080/jspui/handle/123456789/6177

Collections

Informe INCA 399

Endorsement

Review

Supplemented By

Referenced By